Tag: Weight Loss
FDA Approves Wegovy to Lower Risk for CVD Events in Patients With Obesity
Agency's action could widen access to the drug if more insurance companies decide to cover it
Weight Management Treatments Increase Weight Loss in Patients With Obesity
Probability of 5 percent or greater weight loss was increased with year-long exposure to any WMT
Cancer Risk Increased With Recent Weight Loss
Cancer diagnoses more common among those whose weight loss was classified as unintentional
Type 2 Diabetes Remission Likely With Weight Loss After Diagnosis
Increased likelihood of diabetes remission and reduced risk for returning to hyperglycemia seen with weight loss in year after diagnosis
Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent Effects
Prior to weight loss, liraglutide improves insulin sensitivity; reductions in fasting and postprandial glucose also seen
FDA Finds No Evidence Linking Wegovy, Ozempic to Suicidal Behaviors
However, the agency noted officials cannot rule out that 'a small risk may exist,' and it will continue to investigate
Prevalence of Weight Loss Product Use 5.5 Percent in Teens
Prevalence ranged from 2.0 percent in past week to 8.9 percent in lifetime; use was higher among girls than boys
Risk for Suicidal Ideation Not Increased With Semaglutide
No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications
New Side Effects Reported for GLP-1 RA Weight-Loss Drugs
FDA is investigating reports of hair loss, aspiration, and suicidal thoughts among people taking the medications
One-Third of Patients Persist on Antiobesity Medications at Six Months
Semaglutide associated with the highest persistence at one year
